Laureate Pharma Reports Consecutive Quarter of Record-Breaking Performance

    Strong Momentum of Client Project Pipeline Drives 223% Revenue Growth and
    Positive EBITDA for Second Quarter in a Row

    PRINCETON, N.J., Nov. 7 /CNW/ -- Laureate Pharma, Inc., a full- service
biopharmaceutical development and protein production company, today announced
its fourth consecutive record-breaking quarterly results for the period ending
September 30, 2007, posting a 223% increase in revenues over the same period
last year and generating positive EBITDA for the second quarter in a row.
Laureate has expanded its customer base with several new biopharmaceutical
manufacturing and aseptic filling agreements. The company's healthy prospects
-- future revenues from signed contracts -- are expected to provide strong
momentum to achieve 2007 objectives and a solid base for revenues in 2008. As
part of its growth strategy, Laureate is continuing to increase its workforce
to 111 employees by the end of the year and expand its cGMP manufacturing
capacity at its facility located in Princeton, NJ.
    (Logo: )
    "We are pleased that strong demand for our services continues to fuel the
growth of our business," said Robert Broeze, Ph.D., President and Chief
Executive Officer of Laureate Pharma. "We closed Q3 2007 with our fourth
consecutive record quarter, an impressive list of clients, a portfolio of
active projects and a robust pipeline of new business on the horizon. We are
committed to achieving our goal of being EBITDA positive for the year and
exceeding our 2007 business objectives."
    "Having superior contract manufacturing service offerings, infrastructure
and expertise, Laureate continues to capture a significant share of the market
for biopharmaceutical manufacturing," said James A. Datin, Executive Vice
President and Managing Director of the Life Sciences Group at Safeguard
Scientifics. "Laureate continues to augment its organization and generate a
solid pipeline of manufacturing and filling agreements. We are excited by the
opportunities ahead for Laureate and look forward to its continued growth."
    About Laureate Pharma
    Laureate Pharma, Inc. is a full-service biopharmaceutical development and
protein production company located in Princeton, New Jersey. Laureate Pharma
offers superior bioprocessing services that accelerate new products from
development through production. We provide a wide range of specialized
services from process design and development to full-scale cGMP manufacturing,
purification, aseptic filling, testing, validation, analytical services, and
regulatory support. Our business is focused on two active segments of the
biopharmaceutical industry: monoclonal antibodies and recombinant protein
products. Laureate Pharma is a wholly owned subsidiary of Safeguard
Scientifics, Inc. For more information, contact Michael Cavanaugh, Vice
President Sales, Marketing, and Business Development at (609) 919-3400, or or visit our web site at
    About Safeguard
    Safeguard Scientifics, Inc. (NYSE:   SFE), a holding company, builds value
in growth-stage technology and life sciences businesses. Safeguard provides
growth capital as well as a range of strategic, operational and management
resources to its partner companies. Safeguard participates in growth buyout
financings, including corporate spinouts and management buyouts, expansion
financings, industry consolidations and early-stage financings. For more
information, visit

For further information:

For further information: Michael Cavanaugh, Vice President Sales, 
Marketing, and Business Development of Laureate Pharma, Inc., +1-609-919-3400, Web Site:        

Organization Profile


More on this organization


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890